Medical management of uncomplicated benign prostatic hyperplasia. A new decision algorithm;Prise en charge médicale de l'hypertrophie bénigne de la prostate non compliquée. Proposition d'un nouvel algorithme décisionnel

Presse Medicale

Volumn 36, Issue 3 II, 2007, Pages 475-480

  Desgrandchamps, François ^a   De la Taille, Alexandre ^b   Azouzi, Rahmène ^c   Fourmarier, Marc ^d   Haillot, Olivier ^e   Lukacs, Bertrand ^f   Saussine, Christian ^g  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c Hôpital d'Angers   (United States)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e Hôpital de Tours   (United States)

^f HÔPITAL TENON   (France)

^g Service d'urologie   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; DECISION MAKING; DISEASE DURATION; HUMAN; HYPERTHERMIC THERAPY; MICROWAVE RADIATION; PROSTATE HYPERTROPHY; RADIOFREQUENCY; RISK FACTOR; SHORT SURVEY; SYMPTOM; TREATMENT INDICATION; URINE RETENTION; ALGORITHM; MALE; REVIEW;

ALGORITHMS; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 34047266159     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2006.12.006     Document Type: Short Survey

References (23)

1. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy : the Baltimore longitudinal study of aging. Urology 38 (1991) 4-8
2. Chute C.G., Panser L.A., Girman C.J., Oesterling J.E., Guess H.A., Jacobsen S.J., et al. The prevalence of prostatism : a population-based survey of urinary symptoms. J Urol 150 (1993) 85-89
3. Girman C.J., Panser L.A., Chute C.G., Oesterling J.E., Barrett D.M., Chen C.C., et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 150 (1993) 887-892
4. Piercy G.B., Deber R., Trachtenberg J., Ramsey E.W., Norman R.W., Goldenberg S.L., et al. Impact of a shared decision-making program on patients with benign prostatic hyperplasia. Urology 53 (1999) 913-920
5. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2385-2396
6. Lowe F.C., Batista J., Berges R., Chartier-Kastler E., Conti G., Desgrandchamps F., et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 8 (2005) 206-209
7. Emberton M., Andriole G.L., de la Rosette J., Djavan B., Hoefner K., Vela Navarrete R., et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61 (2003) 267-273
8. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54 (1999) 662-669
9. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
10. Fitzpatrick J.M., and Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 95 (2005) 575-579
11. Debruyne F., Koch G., Boyle P., Da Silva F.C., Gillenwater J.G., Hamdy F.C., et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41 (2002) 497-506
12. AUA practice guidelines committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
13. Boyle P., Robertson C., Lowe F., and Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 (2004) 751-756
14. Hutchison A., Farmer R., Verhamme K., Berges R., and Navarrete R.V. The Efficacy of Drugs for the Treatment of LUTS/BPH, A Study in 6 European Countries. Eur Urol (2006) (in press)
15. Kirby R.S. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 91 (2003) 41-44
16. Verhamme K.M., Dieleman J.P., Bleumink G.S., Bosch J.L., Stricker B.H., and Sturkenboom M.C. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44 (2003) 539-545
17. Desgrandchamps F., and Mongiat-Artus P. Dosage and duration of medication for men with lower urinary tract symptoms: two questions without definitive answers. Curr Opin Urol 16 (2006) 37-39
18. Barkin J., Guimaraes M., Jacobi G., Pushkar D., Taylor S., and van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
19. Lee J.Y., Kim H.W., Lee S.J., Koh J.S., Suh H.J., and Chancellor M.B. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
20. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 14 (2004) 17-20
21. Zlotta A.R., Giannakopoulos X., Maehlum O., Ostrem T., and Schulman C.C. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44 (2003) 89-93
22. Tan A.H., Nott L., Hardie W.R., Chin J.L., Denstedt J.D., and Razvi H. Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 19 (2005) 1191-1195
23. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and de la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554